A pilot study evaluating biomarker development for drug-induced chronic eczematous eruptions of aging individuals.

Background: Identifying the drug(s) responsible for drug-induced chronic eczematous eruptions of aging individuals (CEEA) is a clinical challenge in patients on multiple medications. Reliable testing methods and biomarkers are needed to identify the causative agent and allow simultaneous assessment of T-cell responses to multiple drugs being taken concurrently. This study examined the feasibility of using , drug-specific T cell activation responses as a biomarker for drug-induced CEEA.